SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that data from three studies related to its early stage scientific programs will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) being held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
Details on the three poster presentations are as follows:
| Title: | Vascular-based Strategies for Enhancing Tumour Response to Radiation Administered in a Stereotactic Schedule |
| Authors: | Michael R. Horsman, Ph.D. and Thomas R. Wittenborn, Ph.D. |
| Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark | |
| Abstract: | 850 |
| Session Title: | Radiation Oncology: Modifiers and Signal Transduction, Sensitivity, Resistance, and Therapy |
| Session Category: | Experimental and Molecular Therapeutics 7 |
| Date/Time/Location: | Sunday, April 6, 2014 1:00 – 5:00 p.m. Halls A-E, Poster Section 35 |
| Title: | Assessment of Anti-Tumour Activity of the Cathepsin L Inhibitor, KGP94 |
| Authors: | Thomas R. Wittenborn, Ph.D. 1 , Michael Stratford, Ph.D. 2 , Mary Lynn Trawick, Ph.D. 3 , Kevin G. Pinney, Ph.D., 3 David J. Chaplin, Ph.D. 4 , Dietmar W. Siemann, Ph.D. 5 , Michael R.Horsman, Ph.D. 1 |
| 1 Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark | |
| 2 Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, U.K. | |
| 3 Department of Chemistry and Biochemistry, Baylor University, Waco, Texas, U.S.A. | |
| 4 OXiGENE Inc., South San Francisco, California, U.S.A. | |
| 5 Department of Radiation Oncology, University of Florida, Gainesville, Florida, U.S.A. | |
| Abstract: | 1816 |
| Session Title: | Novel Targets 1 |
| Session Category: | Experimental and Molecular Therapeutics 14 |
| Date/Time/Location: | Monday, April 7, 2014 8:00 a.m. – 12:00 p.m. Halls A-E, Poster Section 33 |
| Title: | In-vivo Evaluation of the Anti-metastatic Efficacy of Small Molecule Cathepsin L Inhibitor KGP94 in a Prostate Cancer Model |
| Authors: | Dhivya Sudhan, Ph.D. 1 and Dietmar W. Siemann, Ph.D. 2 |
| 1 Department of Pharmacology & Therapeutics, University of Florida, Gainesville, Florida, U.S.A. | |
| 2 Department of Radiation Oncology, University of Florida, Gainesville, Florida, U.S.A. | |
| Abstract: | 4030 |
| Session Title: | Therapeutic Approaches for Metastatic Tumors |
| Session Category: | Tumor Biology |
| Date/Time/Location: | Tuesday, April 8, 2014, 1:00 – 5:00 p.m. Halls A-E, Poster Section 7 |
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company's lead clinical product candidate, ZYBRESTAT ® , is in development as a potential treatment for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
Investor and Media Contact: 650-635-7000
